Corpus overview


MeSH Disease

COVID-19 (26)

Leukocytosis (26)

Fever (10)

Fatigue (8)

Diarrhea (8)

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


SARS-CoV-2 Proteins
    displaying 1 - 10 records in total 26
    records per page

    High Dependency Renal Unit ( HDRU MESHD) for the management of COVID-19 MESHD in patients with severe acute or chronic kidney disease MESHD

    Authors: Sayali Thakare; Tulsi Modi; Chintan Gandhi; Sreyashi Bose; Satrupa Deb; Abhinav Katyal; Nikhil Saxena; Ankita Patil; Sunil Patil; Atim Pajai; Divya Bajpai; Pratap Jadhav; Tukaram Jamale

    doi:10.21203/ Date: 2021-02-12 Source: ResearchSquare

    Background: COVID-19 MESHD in patients on dialysis for acute or chronic kidney disease MESHD is associated with high mortality. We evaluated the effect of high dependency renal unit ( HDRU MESHD) with nephrologists as primary care physicians for management of these patients. Methods: This was an observational, cohort study conducted at a tertiary care teaching hospital in western India. Patients needing dialysis for COVID-19 MESHD associated Acute Kidney Injury MESHD (AKI-D) and patients with End-Stage-Renal-Disease MESHD ( ESRD MESHD) hospitalized for COVID-19 MESHD were included in the study. After 2 months into the pandemic (28 March to 28 May), HDRU MESHD was commissioned for management of these patients. With nephrologists as primary care physicians, the components of care included completion of care bundle focusing on key nephrology and COVID-19 MESHD related issues, checklist-based clinical monitoring, integration of multispecialty care, and training of nurses and doctors. Primary outcome of the study was in hospital mortality compared between pre-HDRU and HDRU cohorts. Secondary outcomes were- dialysis dependence in AKI-D, and predictors of death MESHD. Results: 238 of 4052 (5.87%) patients with COVID-19 MESHD admitted from 28th March to 30th September had severe renal impairment MESHD (116 AKI-D and 122 ESRD MESHD). 133 of 238 (56.8%) has severe COVID-19 MESHD. HDRU care was delivered from 28th May to 30th August. Kaplan-Meier survival analysis showed significant improvement in survival after implementation of HDRU [19 of 52 (36.5%) in pre-HDRU versus 35 of 160 (21.9%) in HDRU died, p=<0.01]. 44 (67.7%) AKI-D survivors were dialysis dependent at discharge. Male sex, breathlessness and altered mental status at presentation, development of shock during hospital stay and leukocytosis MESHD predicted mortality. Conclusions: HDRU managed nephrologists as primary care physicians is feasible and potentially effective approach to improve the outcomes of patients with COVID-19 MESHD and severe renal impairment MESHD.

    Clinical Characteristics of Severe COVID-19 MESHD in China: A Case Series and Meta-analysis

    Authors: Geling Teng; Hua Hu; Xia Wang; Junsheng Wang; Hongmei Zhang; Ying Chen

    doi:10.21203/ Date: 2021-01-29 Source: ResearchSquare

    Background: There have been inconsistent reports regarding the unique manifestations of severe coronavirus disease 2019 MESHD ( COVID-19 MESHD) occurring in China. This study analyzed the clinical manifestation of 13 severe COVID-19 MESHD cases at a single institution and compared the data to previously reported characteristics of severe COVID-19 MESHD in China. Methods: This retrospective case study included patients with severe COVID-19 MESHD who were admitted to the isolation ward of the Shandong Chest Hospital from January 2020 to February 2020. The clinical signs and symptoms, laboratory examination results, imaging features, treatment strategies, and patient prognoses were summarized. A database search was then conducted for studies published through December 2020 documenting characteristics of severe COVID-19 MESHD cases in China. The pooled results for severe COVID-19 MESHD patients in China were calculated by using the random-effects model.Results: A total of 4 severe and 9 critical patients were included from Shandong Chest Hospital. The average patient age was 55.3 (range 23-88) years, and 61.5% of patients were male. Chest computed tomography for all patients showed multiple lesions as ground-glass shadows in both lungs. All patients presented bacterial infection MESHD and various degrees of liver and myocardial injury MESHD. The treatment strategies for patients included antibiotics, immunoglobulin, and glucocorticoids, and mechanical ventilation was used in all patients for respiratory failure MESHD. Two patients died, and 11 recovered. In the pooled data for severe COVID-19 MESHD patients, the most common comorbidities were hypertension MESHD, diabetes mellitus MESHD, and coronary heart disease MESHD. The common signs in these patients were fever MESHD, cough MESHD, fatigue MESHD, chest tightness MESHD, and a leukocyte count > 10. Conclusions: Older males with hypertension MESHD, diabetes mellitus MESHD, and coronary heart disease MESHD may be at higher risk of developing severe COVID-19 MESHD. Patients should be assessed for concomitant bacterial infections MESHD. Cardiac and liver enzymes, fever MESHD, cough MESHD, fatigue MESHD, chest tightness MESHD, and leukocytosis MESHD should be monitored for signs of disease progression. 

    Increased peripheral blood neutrophil activation phenotypes and NETosis in critically ill COVID-19 MESHD patients

    Authors: Jorge A. Masso-Silva PhD; Alexander Moshensky BS; Michael T. Y. Lam MD PhD; Mazen Odish MD; Arjun Patel MBBS; Le Xu PhD; Emily Hansen MS; Samantha Trescott BS; Celina Nguyen BS; Roy Kim BS; Katherine Perofsky MD; Samantha Perera N/A; Lauren Ma BS; Josephine Pham N/A; Mark Rolfsen MD; Jarod Olay MS; John Shin BS; Jennifer M. Dan MD PhD; Robert Abbott PhD; Sydney Ramirez MD PhD; Thomas H. Alexander MD MHSc; Grace Y. Lin MD; Ana Lucia Fuentes MD; Ira N. Advani BS; Deepti Gunge BS; Victor Pretorius MBChB MD; Atul Malhotra MD; Xin Sun PhD; Jason Duran MD PhD; Shane Crotty PhD; Nicole G. Coufal MD PhD; Angela Meier MD PhD; Laura E. Crotty Alexander MD

    doi:10.1101/2021.01.14.21249831 Date: 2021-01-15 Source: medRxiv

    BackgroundIncreased inflammation MESHD is a hallmark of COVID-19 MESHD, with pulmonary and systemic inflammation MESHD identified in multiple cohorts of patients. Definitive cellular and molecular pathways driving severe forms of this disease remain uncertain. Neutrophils, the most numerous leukocytes in blood circulation, can contribute to immunopathology in infections, inflammatory diseases MESHD and acute respiratory distress syndrome MESHD ( ARDS MESHD), a primary cause of morbidity and mortality in COVID-19 MESHD. Changes in multiple neutrophil functions and circulating cytokine levels over time during COVID-19 MESHD may help define disease severity and guide care and decision making. MethodsBlood was obtained serially from critically ill COVID-19 MESHD patients for 11 days. Neutrophil oxidative burst, neutrophil extracellular trap formation (NETosis), phagocytosis and cytokine levels were assessed ex vivo. Lung tissue was obtained immediately post-mortem for immunostaining. ResultsElevations in neutrophil-associated cytokines IL-8 HGNC and IL-6 HGNC, and general inflammatory cytokines IP-10 HGNC, GM-CSF HGNC, IL-1b HGNC, IL-10 and TNF MESHD, were identified in COVID-19 MESHD plasma both at the first measurement and at multiple timepoints across hospitalization (p < 0.0001). Neutrophils had exaggerated oxidative burst (p < 0.0001), NETosis (p < 0.0001) and phagocytosis (p < 0.0001) relative to controls. Increased NETosis correlated with both leukocytosis and neutrophilia MESHD. Neutrophils and NETs were identified within airways and alveoli in the lung parenchyma of 40% of SARS-CoV-2 infected lungs MESHD. While elevations in IL-8 HGNC and ANC correlated to COVID-19 MESHD disease severity, plasma IL-8 HGNC levels alone correlated with death MESHD. ConclusionsCirculating neutrophils in COVID-19 MESHD exhibit an activated phenotype with increased oxidative burst, NETosis and phagocytosis. Readily accessible and dynamic, plasma IL-8 HGNC and circulating neutrophil function may be potential COVID-19 MESHD disease biomarkers.

    Cerebrospinal fluid in COVID-19 MESHD neurological complications: no cytokine storm or neuroinflammation.

    Authors: Maria A. Garcia; Paula V. Barreras; Allie Lewis; Gabriel Pinilla; Lori J. Sokoll; Thomas Kickler; Heba Mostafa; Mario Caturegli; Abhay Moghekar; Kathryn C. Fitzgerald; - Hopkins Neuro-COVID-19 Group; Carlos A Pardo

    doi:10.1101/2021.01.10.20249014 Date: 2021-01-12 Source: medRxiv

    BACKGROUND. Neurological complications MESHD occur in COVID-19 MESHD. We aimed to examine cerebrospinal fluid (CSF) of COVID-19 MESHD subjects with neurological complications MESHD and determine presence of neuroinflammatory changes implicated in pathogenesis. METHODS. Cross-sectional study of CSF neuroinflammatory profiles from 18 COVID-19 MESHD subjects with neurological complications categorized by diagnosis ( stroke MESHD, encephalopathy MESHD, headache MESHD) and illness severity (critical, severe, moderate, mild). COVID-19 MESHD CSF was compared with CSF from healthy, infectious and neuroinflammatory disorders MESHD and stroke MESHD controls (n=82). Cytokines ( IL-6 HGNC, TNF-alpha HGNC, IFN-gamma HGNC, IL-10 HGNC, IL-12p70, IL-17A HGNC), inflammation MESHD and coagulation markers (high-sensitivity- C Reactive Protein HGNC [hsCRP], ferritin, fibrinogen HGNC, D-dimer, Factor VIII) and neurofilament light chain ( NF-L HGNC), were quantified. SARS-CoV2 RNA and SARS-CoV2 IgG and IgA antibodies in CSF were tested with RT-PCR and ELISA. RESULTS. CSF from COVID-19 MESHD subjects showed a paucity of neuroinflammatory changes, absence of pleocytosis MESHD or specific increases in pro-inflammatory markers or cytokines ( IL-6 HGNC, ferritin, or D-dimer). Anti-SARS-CoV2 antibodies in CSF of COVID-19 MESHD subjects (77%) were observed despite no evidence of SARS-CoV2 viral RNA. A similar increase of pro-inflammatory cytokines ( IL-6 HGNC, TNF-alpha HGNC;, IL-12p70) and IL-10 HGNC in CSF of COVID-19 MESHD and non- COVID-19 MESHD stroke MESHD subjects was observed compared to controls. CSF-NF-L was elevated in subjects with stroke MESHD and critical COVID-19 MESHD. CSF-hsCRP was present almost exclusively in COVID-19 MESHD cases. CONCLUSION. The paucity of neuroinflammatory changes in CSF of COVID-19 MESHD subjects and lack of SARS-CoV2 RNA do not support the presumed neurovirulence of SARS-CoV2 or neuroinflammation MESHD in pathogenesis of neurological complications in COVID-19 MESHD. Elevated CSF-NF-L indicates neuroaxonal injury MESHD in COVID-19 MESHD cases. The role of CSF SARS-CoV2 IgG antibodies is still undetermined.

    Early triage of patients diagnosed with COVID-19 MESHD based on predicted prognosis: A Korean national cohort study

    Authors: Chansik An; Hyun Cheol Oh; Jung Hyun Chang; Sung Jin Oh; Jung Mo Lee; Chang Hoon Han; Seong Woo Kim

    doi:10.21203/ Date: 2020-11-18 Source: ResearchSquare

    We developed a tool for early triage of a COVID-19 MESHD patient based on a predicted prognosis, using a Korean national cohort of 5,596 patients. Predictors chosen for our model were older age, male sex, subjective fever MESHD, dyspnea MESHD, altered consciousness, temperature ≥ 37.5°C, heart rate ≥ 100 bpm, systolic blood pressure ≥ 160 mmHg, diabetes mellitus MESHD, heart disease MESHD, chronic kidney disease MESHD, cancer MESHD, dementia MESHD, anemia MESHD, leukocytosis MESHD, lymphocytopenia MESHD, and thrombocytopenia MESHD. Our model was better in predicting prognosis than protocols that are not based on data. The AUC of our model utilizing all the selected predictors was 0.907 in predicting whether a patient will require at least oxygen therapy and 0.927 in predicting whether a patient will need critical care or die from COVID-19 MESHD. Even with age, sex, and symptoms alone used as predictors, AUCs were ≥ 0.88. In contrast, the protocols currently recommended in Korea showed AUCs less than 0.75.

    Clinical characteristics, outcomes, and risk factors for mortality in hospitalized patients with COVID-19 MESHD and cancer history: a propensity score-matched study

    Authors: Majid Sorouri; Amir Kasaeian; Helia Mojtabavi; Amir Reza Radmard; Shadi Kolahdoozan; Amir Anushiravani; Bardia Khosravi; Seyed Mohammad Pourabbas; Masoud Eslahi; Azin Sirusbakht; Marjan Khodabakhshi; Fatemeh Motamedi; Fatemeh Azizi; Reza Ghanbari; Ali Reza Sima; Soroush Rad; Mohammad Abdollahi

    doi:10.21203/ Date: 2020-10-26 Source: ResearchSquare

    Background: COVID-19 MESHD has caused great concern for patients with underlying medical conditions. We aimed to determine the prognosis of patients with current or previous cancer MESHD with either a PCR-confirmed COVID-19 MESHD infection or a probable diagnosis according to chest CT scan.Methods: We conducted a case control study in a referral hospital on confirmed COVID-19 MESHD adult patients with and without a history of cancer MESHD from February25th to April21st, 2020. Patients were matched according to age, gender, and underlying diseases. Demographic features, clinical and Para clinical data have been extracted from medical records. Multivariable logistic regression was used to estimate odd ratios and 95% confidence intervals of each factor of interest with outcomes. Results: Fifty-three confirmed COVID-19 MESHD patients with history of cancer MESHD were recruited and compared with 106 non-cancerous COVID-19 MESHD patients. Male to female ratio was 1.33 and 45% were older than 65. Dyspnea MESHD was significantly associated with an increased rate of mortality in the cancer MESHD subgroup (p=0.013). Twenty-six patients (49%) survived among the cancer MESHD group while 89 patients (84%) survived in control (p=0.000). Patients with hematologic cancer MESHD had 63% mortality while those with solid tumors MESHD had 37%. Multivariate analysis showed that cancer MESHD, impaired consciousness MESHD, tachypnea MESHD, tachycardia MESHD, leukocytosis MESHD and thrombocytopenia MESHD were associated with an increased risk of death MESHD.Conclusion: Cancer increased mortality rate and hospital stay of COVID-19 MESHD patients and remained significant after adjustment of confounders. Compared to solid tumors MESHD, hematologic malignancies MESHD have been associated with worse consequences and higher mortality. Clinical and Para clinical indicators were not appropriate to predict death MESHD.

    Spectrum of spinal cord involvement in COVID-19 MESHD: A systematic review

    Authors: Ritwick Mondal; Shramana Deb; Gourav Shome; Upasana Ganguly; Durjoy Lahiri; Julian Benito Leon

    doi:10.1101/2020.09.29.20203554 Date: 2020-09-30 Source: medRxiv

    Background and aims- Recent reports reveal incidences of spinal cord involvement in form of para-infectious MESHD or post-infectious myelitis MESHD raising potential concerns about the possibilities of SARS-CoV-2 behind the pathogenesis of spinal cord demyelination MESHD. In this study, we intend to summarise so far available pieces of evidence documenting SARS-CoV-2 mediated spinal demyelination MESHD in terms of clinical, laboratory parameters and imaging characteristics. Methodology- This review was carried out based on the existing PRISMA (Preferred Report for Systemic Review and Meta-analyses) consensus statement. Data was collected from four databases: Pubmed/Medline, NIH Litcovid, Embase and Cochrane library and Preprint servers up till 10th September, 2020. Search strategy comprised of a range of keywords from relevant medical subject headings which includes "SARS-COV-2", " COVID-19 MESHD", " demyelination MESHD" etc. Results- A total of 21 cases were included from 21 case reports after screening from various databases and preprint servers. Biochemical analysis reveals that the majority of cases showed elevated CSF HGNC protein as well as lymphocytic pleocytosis MESHD. Interestingly, a majority of cases were found to be associated with long extensive transverse myelitis MESHD (LETM), and remaining cases were found to be associated with isolated patchy involvement or isolated short segment involvement or combined LETM and patchy involvement. Few cases were also found with significant co-involvement of the brain and spine based on the imaging data. Conclusion- It can be interpreted that SARS-CoV-2 may play a potential role in spinal demyelinating disorders MESHD in both para-infectious MESHD and post-infectious forms.

    A Systematic Review and Meta-analysis of Pregnancy and COVID-19 MESHD: Signs and Symptoms, Laboratory Tests and Perinatal Outcomes

    Authors: Soheil Hassanipour; Saeed Bagheri Faradonbeh; Khalil Momeni; Zahra Heidarifard; Mohammad-Javad Khosousi; Leila Khosousi; Hosein Ameri; Morteza Arab-Zozani

    doi:10.1101/2020.09.28.20202945 Date: 2020-09-28 Source: medRxiv

    Background: COVID-19 MESHD caused by severe acute respiratory syndrome MESHD coronavirus 2 appeared in December 2019 in Wuhan, China. Objective: We aimed to investigate the clinical manifestation include signs and symptoms, laboratory results, and perinatal outcomes in pregnant women with COVID-19 MESHD. Materials and Methods: We searched PubMed via LitCovid hub, Embase, Scopus, Web of sciences, and Google scholar on 07 April 2020. Meta-analysis was performed via CMA software using the Mantel-Haenszel method. The event rate with 95% CI was calculated for each variable. Results: Ten studies were selected. The pooled prevalence for fever MESHD, post-partum fever MESHD, cough MESHD, myalgia MESHD, fatigue MESHD, dyspnea MESHD, sore throat, and diarrhea MESHD were 66.8 %, 37.1 %, 35.5 %, 24.6 %, 14.9%, 14.6 %, 11.5%, and 7.6 %, respectively. Laboratory test results were 49.8 % for lymphopenia MESHD, 47.7 % for leukocytosis MESHD, 83.7 % for elevated neutrophil ratio, 57 % for elevated C-reactive protein HGNC, and 71.4 % for decreased lymphocyte ratio. The rate of cesarean section for delivery in all cases was 84%. Only one case was the newborn of a mother with COVID-19 MESHD positive. Also, there was only one death due to Decreased lymphocyte ratio. Conclusion: Fever MESHD was the most common signs and symptoms in pregnant women with COVID-19 MESHD. Among the laboratory tests, the highest amount was related to elevated neutrophil ratio. It seems that due to the differences between pregnant women and the general population, special measures should be considered to treat these patients.

    Review of clinical characteristics and laboratory findings of COVID-19 MESHD in children-Systematic review and Meta-analysis

    Authors: Harmeet K Kharoud; Rizwana Asim; Lianne Siegel; Lovepreet Chahal; Gagan Deep Singh

    doi:10.1101/2020.09.23.20200410 Date: 2020-09-25 Source: medRxiv

    OBJECTIVE: To conduct a systematic review and meta-analysis to assess the prevalence of various clinical symptoms and laboratory findings of COVID-19 MESHD in children. METHODS: PubMed, MEDLINE, and SCOPUS databases were searched to include studies conducted between January 1, 2020, and July 15, 2020 which reported data about clinical characteristics and laboratory findings in laboratory-confirmed diagnosis of COVID-19 MESHD in pediatric patients. Random effects meta-analysis using generalized linear mixed models was used to estimate the pooled prevalence. RESULTS: The most prevalent symptom of COVID-19 MESHD in children was 46.17% (95%CI 39.18-53.33%), followed by cough (40.15%, 95%CI 34.56-46.02%). Less common symptoms were found to be dyspnea MESHD, vomiting MESHD, nasal congestion/ rhinorrhea MESHD, diarrhea MESHD, sore throat/pharyngeal congestion, headache MESHD, and fatigue MESHD. The prevalence of asymptomatic children was 17.19% (95%CI 11.02-25.82%). The most prevalent laboratory findings in COVID-19 MESHD children were elevated Creatinine Kinase (26.86%, 95%CI 16.15-41.19%) and neutropenia MESHD (25.76%, 95%CI 13.96-42.58%). These were followed by elevated LDH, thrombocytosis MESHD, lymphocytosis MESHD, neutrophilia, elevated D Dimer, Elevated CRP, elevated ESR, leukocytosis MESHD, elevated AST HGNC and leukopenia MESHD. There was a low prevalence of elevated ALT and lymphopenia MESHD in children with COVID- 19. CONCLUSIONS AND RELEVANCE: This study provides estimates of the pooled prevalence of various symptoms and laboratory findings of COVID-19 MESHD in the pediatric population.

    Acute Transverse Myelitis After SARS-CoV-2 Infection MESHD: A Rare Complicated Case of Rapid Onset Paraplegia in a Male Veteran 

    Authors: Ebrahim Hazrati; Ramin Hamidi Farahani; Amir Nezami Asl; Hamze Shahali

    doi:10.21203/ Date: 2020-08-30 Source: ResearchSquare

    Background: SARS-CoV-2 ( COVID-19 MESHD) is a new human pathogen, and currently, the world has been plagued by its pandemic and there are no specific treatment options, mostly affects the respiratory system, ranging from mild flu-like symptoms to severe acute r espiratory syndrome MESHD(SARS), but extra respiratory multi-systemic involvement has also been reported.Case presentation: A 63-yr-old Caucasian male veteran (retired army colonel), known case of controlled T ype 2 diabetes, MESHD c hronic renal failure MESHDand i schemic MESHDh eart disease, MESHD about 4 days after the onset of f lu-like syndrome MESHD(with no t rauma MESHDhistory) experienced loss of control over both lower limbs, absent sensation from the chest below with c onstipation MESHDand urinary retention. Due to world SARS-CoV-2 ( COVID-19 MESHD) outbreak, his nasopharyngeal specimen was tested for COVID-19 MESHD reverse transcription polymerase chain reaction (RT-PCR) and positive result obtained. Chest x-ray and HRCT suggested severe pulmonary involvement. Immediately, he was admitted at emergency ward, treated based national COVID-19 MESHD protocol and a series of diagnostic procedures were started up to find out the cause of his non-heterogeneous peripheral (spinal) neuromuscular manifestations. Brain CT scan and MRI were normal, but spinal MRI with gadolinium contrast agent showing extensive increased T2 signal involves central grey matter and dorsal columns, extension between C7 and T12 with linear sagittally oriented enhancement posteriorly within the cord in the mid and lower thoracic cord. The CSF specimen obtained from LP shown p leocytosis, MESHD positive RT-PCR for SARS-CoV-2 and elevated IgG index. Clinical presentations, MRI, CSF and laboratory findings, after ruled out the other numerous possible causes with specific methods, suggested the A cute Transverse Myelitis MESHD(A TM) HGNC TM) MESHD as a probably complication of COVID-19 MESHD i nfection. MESHD Intravenous methylprednisolone and then human immunoglobulin was added to treatment regimen. At the end, complete resolution of d ysaesthesia, urinary retention MESHDand c onstipation MESHDwere achieved. After continuous and long respiratory and motor rehabilitation programs, he was discharged home asymptomatic. Conclusions: We believe that SARS-CoV-2 has a potential to produces different extra respiratory multi-systemic involvement as immune-mediated process and complexes, and this should be kept in mind whenever encounter a patient with acute onset of neurological manifestations, especially after m icrobial infections MESHDor vaccinations.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.